8 results
PREM14A
GYRE
Gyre Therapeutics Inc
30 Mar 23
Preliminary proxy related to merger
4:48pm
to the Contributions. The cash and perquisites/benefits disclosure provided by this table is quantified assuming that the following events occur on March 1, 2023 … by Catalyst’s named executive officers may differ in material respects from the amounts set forth below.
Name
Cash
($)(1)
Equity
($)(2)
Perquisites/Benefits
8-K
EX-2.1
0qkt 6h6m3
6 Mar 15
Targacept and Catalyst Biosciences Enter Definitive Merger Agreement Creating a Protease-Based Hemostasis and Anti-Complement Company
12:00am
425
EX-2.1
9caz 5uv1v7z
6 Mar 15
Business combination disclosure
12:00am
- Prev
- 1
- Next